BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36561717)

  • 1. Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis.
    Parthasarathy V; Cravero K; Deng J; Sun Z; Engle SM; Auxier AN; Hahn N; Sims JT; Okragly AJ; Alphonse MP; Kwatra SG
    Front Med (Lausanne); 2022; 9():1011142. PubMed ID: 36561717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans.
    Sutaria N; Alphonse MP; Marani M; Parthasarathy V; Deng J; Wongvibulsin S; Williams K; Roh YS; Choi J; Bordeaux Z; Pritchard T; Dillen C; Semenov YR; Kwatra MM; Archer NK; Garza LA; Dong X; Kang S; Kwatra SG
    J Invest Dermatol; 2022 May; 142(5):1300-1308.e3. PubMed ID: 34717952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis.
    Parthasarathy V; Cravero K; Xu L; Deng J; Sun Z; Engle SM; Sims JT; Okragly AJ; Kwatra SG
    J Am Acad Dermatol; 2023 May; 88(5):1101-1109. PubMed ID: 36806647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation.
    Cornman HL; Manjunath J; Reddy SV; Adams J; Rajeh A; Samuel C; Bao A; Zhao R; Ma EZ; Shumsky J; Pritchard TW; Imo BU; Kollhoff AL; Lee KK; Lu W; Yossef S; Kwatra MM; Kwatra SG
    Sci Rep; 2024 Apr; 14(1):8098. PubMed ID: 38582943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. REMOVED: Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis.
    Chu L; Wang LK; Wu Y; Yang H; Wang W; Lu Q; Deng H
    Actas Dermosifiliogr; 2022 Mar; 113(3):244-253. PubMed ID: 35282859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REMOVED: Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis.
    Chu L; Wang L; Wu Y; Yang H; Wang W; Lu Q; Deng H
    Actas Dermosifiliogr; 2022 Mar; 113(3):T244-T253. PubMed ID: 35331446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta.
    Hashimoto T; Nattkemper LA; Kim HS; Kursewicz CD; Fowler E; Shah SM; Nanda S; Fayne RA; Paolini JF; Romanelli P; Yosipovitch G
    Exp Dermatol; 2021 Jun; 30(6):804-810. PubMed ID: 33428793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis.
    Sutaria N; Marani M; Choi J; Roh YS; Parthasarathy V; Deng J; Bordeaux ZA; Taylor MT; Lee KK; Pritchard T; Alajmi A; Adawi W; Semenov YR; Alphonse MP; Kwatra SG
    J Dermatol Sci; 2022 Feb; 105(2):130-136. PubMed ID: 35151532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
    Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
    JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
    Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
    JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal Plasma Levels of Steroids and Their Ratios in Patients With Prurigo Nodularis: A Pilot Study.
    Chu L; Shu X; Wu Y; Yang H; Lu Q; Deng H
    Front Physiol; 2022; 13():835269. PubMed ID: 35837010
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased IL-31 expression in serum and tissue protein in prurigo nodularis.
    Chaowattanapanit S; Wongjirattikarn R; Chaisuriya N; Ungarreevittaya P; Poosekeaw P; Winaikosol K; Choonhakarn C; Julanon N; Salao K
    Ther Adv Chronic Dis; 2022; 13():20406223221112561. PubMed ID: 35875833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.
    Janmohamed SR; Gwillim EC; Yousaf M; Patel KR; Silverberg JI
    Arch Dermatol Res; 2021 Oct; 313(8):669-677. PubMed ID: 33108524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethnic differences and comorbidities of 909 prurigo nodularis patients.
    Boozalis E; Tang O; Patel S; Semenov YR; Pereira MP; Stander S; Kang S; Kwatra SG
    J Am Acad Dermatol; 2018 Oct; 79(4):714-719.e3. PubMed ID: 29733939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis.
    Hughes JM; Woo TE; Belzberg M; Khanna R; Williams KA; Kwatra MM; Hassan S; Kwatra SG
    Medicines (Basel); 2020 Jan; 7(1):. PubMed ID: 31936197
    [No Abstract]   [Full Text] [Related]  

  • 16. Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.
    Belzberg M; Alphonse MP; Brown I; Williams KA; Khanna R; Ho B; Wongvibulsin S; Pritchard T; Roh YS; Sutaria N; Choi J; Jedrych J; Johnston AD; Sarkar K; Vasavda C; Meixiong J; Dillen C; Bondesgaard K; Paolini JF; Chen W; Corcoran D; Devos N; Kwatra MM; Chien AL; Archer NK; Garza LA; Dong X; Kang S; Kwatra SG
    J Invest Dermatol; 2021 Sep; 141(9):2208-2218.e14. PubMed ID: 33771530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.
    Bewley A; Homey B; Pink A
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2039-2048. PubMed ID: 35986886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.
    Tsoi LC; Hacini-Rachinel F; Fogel P; Rousseau F; Xing X; Patrick MT; Billi AC; Berthier CC; Kahlenberg JM; Lazzari A; Wiegmann H; Ständer S; Piketty C; Julia V; Krishnaswamy JK; Gudjonsson JE
    J Allergy Clin Immunol; 2022 Apr; 149(4):1329-1339. PubMed ID: 34857395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of the Skin-Liver Axis in Prurigo Nodularis: An Integrated Genomic, Transcriptomic, and Population-Based Analysis.
    Marani M; Madan V; Le TK; Deng J; Lee KK; Ma EZ; Kwatra SG
    Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.
    Williams KA; Roh YS; Brown I; Sutaria N; Bakhshi P; Choi J; Gabriel S; Chavda R; Kwatra SG
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):67-77. PubMed ID: 33191806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.